All In Biotech

Drug Trial Radar · NCT05445167

A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain

A Phase III Confirmatory Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain

Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

89

Actual

Start

Oct 11, 2022

Primary completion

Feb 16, 2024

Study completion Feb 16, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-center, randomized, double-blind, parallel-group study to confirm superiority of KLH-2109 to placebo in uterine fibroids patient with menorrhagia and pain

Conditions

  • Uterine Fibroids (MeSH Heading: Leiomyoma)

Interventions

  • KLH-2109Drug

    Oral administration

  • PlaceboDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with a total PBAC score of less than 10 from Week 6 to 12 after beginning of study drug administrationTime frame: Up to 12 weeks
  2. Proportion of women with a maximum NRS for pain score of 1 or less during 28 days before the end of study drug administrationTime frame: Up to 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Site

    Multiple Locations, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.